Key result
Sfrp1 overexpression significantly improved cardiac function in aged mice 7 days post-myocardial infarction, increasing fractional shortening to 33.26% compared to 14.45% in controls.
Why the study?
Aged patients with acute myocardial ischemia experience increased mortality and worse prognosis, necessitating more effective treatments targeting Wnt/β-catenin pathway deregulation.
Does Sfrp1 overexpression reduce myocardial injury and improve cardiac function in aged mice with acute myocardial ischemia?
Does Sfrp1 overexpression reduce myocardial injury and improve cardiac function in aged mice with acute myocardial ischemia?
Sfrp1 overexpression protects against acute myocardial ischemia injury in aged mice by inhibiting the Wnt/β-catenin signaling pathway, suggesting a potential gene therapy target.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Sfrp1 gene therapy in aged AMI; leaves open human translation and clinical utility.
BACKGROUND: Aged patients suffering from acute myocardial ischemia (AMI) exhibit an increased mortality rate and worse prognosis, and a more effective treatment is currently in need. In the present study, we investigated potent targets related to Wnt/β-catenin pathway deregulation for AMI injury treatment. METHODS: In the present study, AAV-Sfrp1 was transduced into the myocardium of aged mice, and an AMI model was established in these aged mice to study the effect and molecular mechanism of Sfrp1 overexpression on AMI-induced injury. RESULTS: The results showed that Sfrp1 was successfully overexpressed in the myocardium of aged mice and remarkably reduced Wnt/β-catenin pathway activity in aged mice after AMI, effectively reducing the degree of myocardial fibrosis, inhibiting cardiomyocyte apoptosis, and improving cardiac function. We revealed that the exogenous introduction of Sfrp1 could be considered a promising strategy for improving post-AMI injury in aged mice by inhibiting Wnt/β-catenin pathway activity. CONCLUSIONS: In conclusion, the Wnt/β-catenin pathway potentially represents a key target in AMI in aged mice. Sfrp1 might be used as a small molecule gene therapy drug to improve heart function, reduce the degree of myocardial fibrosis, inhibit cardiomyocyte apoptosis and reduce AMI injury in aged mice by inhibiting the Wnt/β-catenin pathway, thereby effectively protecting aged hearts from AMI injury.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2021) studied Acute myocardial ischemia (n=128). AAV-Sfrp1 vs. dsAVV9-GFP was evaluated on Left ventricular short-axis shortening rate (FS) at 7 days (p=<0.01). Sfrp1 overexpression significantly improved cardiac function in aged mice 7 days post-myocardial infarction, increasing fractional shortening to 33.26% compared to 14.45% in controls.
Synapse has enriched 10 related papers. Consider them for comparative context: